Development of a clinically relevant ovarian cancer model incorporating surgical cytoreduction to evaluate treatment of micro-metastatic disease.
Animals
Cell Line, Tumor
/ transplantation
Cytoreduction Surgical Procedures
Disease Models, Animal
Female
Humans
Hysterectomy
Mice
Neoplasm Micrometastasis
/ therapy
Neoplasm, Residual
Ovarian Neoplasms
/ pathology
Ovary
/ pathology
Peritoneal Cavity
/ pathology
Peritoneal Neoplasms
/ secondary
Salpingo-oophorectomy
Tumor Burden
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
25
06
2020
accepted:
08
11
2020
pubmed:
25
11
2020
medline:
1
7
2021
entrez:
24
11
2020
Statut:
ppublish
Résumé
Mouse models of ovarian cancer commonly transfer large numbers of tumor cells into the peritoneal cavity to establish experimental metastatic disease, which may not adequately model early metastatic spread from a primary tumor site. We hypothesized we could develop an ovarian cancer model that predictably represents micro-metastatic disease. Murine ID8 eLuc-transduced ID8 Mice with primary ovarian tumors established through orthotopic injection develop progressively fatal metastatic ovarian cancer, and benefit from surgical cytoreduction to remove bulky disease. This model enables the analysis of therapeutic regimens designed to target and potentially eradicate established minimal residual disease.
Identifiants
pubmed: 33229044
pii: S0090-8258(20)34117-2
doi: 10.1016/j.ygyno.2020.11.009
pmc: PMC8547140
mid: NIHMS1646135
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
427-437Subventions
Organisme : NCI NIH HHS
ID : T32 CA009515
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest P.D.G. has patents with, received funding from, and was a scientific consultant to Juno Therapeutics. R.G. has received consulting income from Juno Therapeutics, Takeda, Infotech Soft, Celgene, Merck and has received research support from Janssen Pharmaceuticals and Juno Therapeutics, and declares ownership in CellSpace Biosciences.
Références
J Vis Exp. 2010 Nov 28;(45):
pubmed: 21178956
Cell Rep. 2020 Jan 14;30(2):525-540.e7
pubmed: 31940494
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
PLoS One. 2014 Mar 04;9(3):e89527
pubmed: 24594904
Cancer Biol Ther. 2015;16(6):807-20
pubmed: 25894333
Gynecol Oncol. 2008 Feb;108(2):385-94
pubmed: 18036641
Nat Rev Cancer. 2011 Sep 23;11(10):719-25
pubmed: 21941283
Gynecol Oncol. 2016 May;141(2):260-263
pubmed: 26968641
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Brief Bioinform. 2016 May;17(3):393-407
pubmed: 26342128
Carcinogenesis. 2000 Apr;21(4):585-91
pubmed: 10753190
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
J Obstet Gynaecol Res. 2018 Feb;44(2):303-311
pubmed: 29171115
Cancer Immunol Res. 2019 Sep;7(9):1412-1425
pubmed: 31337659
Clin Cancer Res. 2013 Aug 1;19(15):4079-91
pubmed: 23785047
Oncoimmunology. 2012 Mar 1;1(2):172-178
pubmed: 22720238
Sci Rep. 2017 Dec 4;7(1):16827
pubmed: 29203787
Cell. 2017 Aug 24;170(5):927-938.e20
pubmed: 28841418
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Am J Pathol. 2016 May;186(5):1103-13
pubmed: 26993207
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Clin Cancer Res. 2016 Jun 15;22(12):3005-15
pubmed: 26763251
Anticancer Res. 2019 Feb;39(2):815-825
pubmed: 30711962
Curr Opin Oncol. 2014 Sep;26(5):492-500
pubmed: 25036883
PLoS One. 2016 Jun 28;11(6):e0158208
pubmed: 27352023
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14342-6
pubmed: 18794521
Oncotarget. 2016 Jul 26;7(30):47343-47365
pubmed: 27329838
Am J Pathol. 2002 Dec;161(6):2295-309
pubmed: 12466143
J Transl Med. 2015 Jul 29;13:247
pubmed: 26219551
Cancer Immunol Immunother. 2019 Sep;68(9):1515-1526
pubmed: 31515669
J Gynecol Oncol. 2015 Oct;26(4):336-42
pubmed: 26197773
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
J Clin Invest. 2013 Jan;123(1):517-25
pubmed: 23257362